Biomarkers /
CDK2
Overview
Cyclin-dependent kinase 2 (CDK2) is a gene that encodes a member of the serine/threonine protein kinase family that functions in cell cycle regulation. Specifically, the protein is important for the progression from G1 to S phase. Missense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer.
CDK2 is altered in 0.16% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, conventional glioblastoma multiforme, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDK2 are CDK2 Mutation (0.41%), CDK2 Amplification (0.06%), CDK2 R200W (0.03%), CDK2 E28K (0.02%), and CDK2 R199C (0.02%) [3].
Clinical Trials
Significance of CDK2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.